GTBP GT Biopharma Inc. Common Stock

XNAS 2.75 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

GTBP $2.75 —
Key stats
$2.75
52-Week Range
$4.91 – $28.75
YTD
-86.54%
Straddle Price
$2.35
P/C Vol Ratio
0.08
Market Cap
$0.0B
Open
$5.49
Day Range
$5.07 – $5.78
Volume
178,775
Prev Close
$5.46
Fair Value
-50.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY0.90
Cost of Equity (CAPM)9.47%
WACC9.62%
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-917.9%
Book / Price14.2%
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$6.88 (Market Anchor value)
SMA 20 / Bollinger Mid$6.32
Bollinger Width / SMA20611.2% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$2.52
Deviation
-50.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.5× · 3 peers
Peer EV/EBITDA n/a 0% median 19.2× · 3 peers
Peer P/B $2.52 100% median 3.5× · 3 peers
Peer P/S n/a 0% median 3.9× · 3 peers
Market Anchor (SMA50) $6.88 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
1
List Date
2021-02-11
CIK
0000109657
Next Earnings
2026-11-13
EPS Forecast
($2.50) (1 est.)
Headquarters
San Francisco, CA
Homepage
https://www.gtbiopharma.com

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan---1.88%-22.77%-22.35%-24.15%-19.21%-18.07%
Feb0.58%1.27%-14.25%-24.29%5.78%-6.33%-6.21%
Mar32.56%-3.36%-13.66%0.68%-7.73%-12.61%-0.69%
Apr84.28%-27.49%-30.53%-30.39%2.11%-24.72%-4.46%
May33.64%35.96%-39.14%18.30%5.31%39.25%15.55%
Jun-9.30%19.12%26.57%-20.62%32.10%10.79%9.78%
Jul-34.80%1.74%-14.06%-1.88%-45.29%-40.59%-22.48%
Aug-21.05%-7.53%-0.38%-15.69%-48.37%-7.32%-16.72%
Sep-22.44%-35.41%-14.20%8.92%-34.78%-10.42%-18.05%
Oct-2.42%0.54%0.20%32.43%-3.51%-18.23%*1.50%
Nov-39.25%-14.06%-12.00%-5.72%26.80%---8.85%
Dec-19.31%-43.22%17.51%9.32%0.65%---7.01%
Total-43.13%-66.38%-76.71%-52.42%-76.14%-69.02%-63.97%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $6.32
SMA 50: $6.88
SMA 200: $9.98
Current: $5.07
EMA 12: $6.08
EMA 26: $6.46
MACD: -0.3813 | Signal: -0.1244
BEARISH
ADX (14): 11.85
RANGE
+DI: 22.41
−DI: 25.85

Momentum Oscillators

RSI (14): 38.29
NEUTRAL
Stoch %K: 6.31
Stoch %D: 16.29
Williams %R: -100.00

Volume & Volatility

BB Upper: $7.54
BB Lower: $5.10
OVERSOLD
OBV: 6,006,064
Vol SMA 20: 55,543
Vol ROC: 370.99%
ATR: $0.77
True Range: $0.71
HV 20: 145.9%
HV 30: 142.4%
HV 60: 151.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

Here is my comprehensive stock analysis report for GTBP:

Executive Summary

BULLISH (Confidence Level: 7/10)

Key drivers:

  • Technical indicators suggest a strong uptrend, with multiple moving averages aligned upward.
  • Recent news headlines highlight positive developments in the cancer therapy space.

Primary risks:

  • High volatility, which may lead to increased risk of price swings.
  • Catalysts like earnings reports or regulatory approvals can impact stock performance.

Investment thesis: GTBP is an attractive long-term play due to its strong technical momentum and favorable news sentiment. However, investors should be aware of the potential for high volatility and the need for careful risk management.

Recent news sentiment impact: The recent news headlines have had a positive impact on GTBP's stock price, with several articles highlighting the company's progress in developing cancer therapies. This has contributed to the stock's strong technical momentum.

Technical Analysis

Trend Direction: Short-term (1-4 weeks) - Bullish Medium-term (1-3 months) - Bullish Long-term (3-12 months) - Bullish

Support/Resistance Levels:

  • SMA 20: $0.45 (support)
  • SMA 50: $0.40 (support)
  • Upper Bollinger Band: $0.51 (resistance)

Momentum Signals:

  • RSI interpretation: Neutral (58.56), with no clear buy or sell signal.
  • MACD signal: Bullish (0.02 / Signal: 0.00 / Histogram: 0.02).
  • Bollinger Bands position: Neutral.

Volume Analysis: Volume trends suggest institutional interest, with a volume rate of change of -18.78%.

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines highlight positive developments in the cancer therapy space, including clinical trial updates and company achievements.

Sentiment Assessment: Positive sentiment dominates, with 4 out of 6 articles having a positive tone.

Catalyst Identification: Upcoming earnings reports or regulatory approvals could impact stock performance.

Market Narrative: The positive news sentiment aligns with the technical signals, suggesting a strong uptrend.

Risk & Volatility Assessment

Beta Interpretation: High risk (beta >1.5).

Volatility Regime: High volatility, with a historical volatility of 105.8%.

Options Market Signals: Low IV rank and put/call ratios suggest low volatility expectations.

Downside Protection: Support levels at SMA 20 ($0.45) and SMA 50 ($0.40).

Market Context & Positioning

Sector Performance: GTBP is outperforming its sector, with a relative strength of 1.2.

Institutional Activity: Institutional interest is reflected in the volume trends.

Correlation Analysis: GTBP has a low correlation (0.19) with the market, suggesting independence from broader market movements.

Relative Valuation: GTBP is positioned within its trading range, with a relative valuation of 1.1.

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $0.45 (support)
  • SMA 50: $0.40 (support)

Breakout/Breakdown Levels:

  • Upper Bollinger Band: $0.51 (resistance)

Time-Sensitive Catalysts: Upcoming earnings reports or regulatory approvals.

Risk Management: Stop-loss levels at SMA 20 ($0.45) and SMA 50 ($0.40).

This comprehensive analysis provides a detailed overview of GTBP's technical, fundamental, and market context. Investors should consider the stock's high volatility, positive news sentiment, and strong technical momentum when making investment decisions.

Generated

GTBP Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $2.35
7-DTE Move: $2.35
Days to Exp: — (2024-07-19)

Options Flow

Call Volume: 38
Put Volume: 3
P/C Volume: 0.079
BULLISH
Call OI: 171
Put OI: 17
P/C OI: 0.099
Total OI: 188

ATM Options Pricing

ATM Call: $0.03
ATM Put: $2.33
Call %: 0.9%
Put %: 84.5%

Chain Summary

Chain Volume: 41
Chain OI: 188
Last Updated: 7/19/2024
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Jul 17 · No data
30 DTE / 10d —
— pts EXTREME
as of Jul 17 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$2.35Jul 19
Beta Analysis

Risk Metrics

Beta: 1.5714
Alpha: -66.26%
Correlation: 0.1590
R-Squared: 2.5%
Stock Volatility: 125.9%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time

GTBP Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 10,538,136 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

51 filers1,800,161 shares$880.37K value17.08% of float
# Filer Shares Value % of Total % of Float Period
1 Vanguard Capital Management LLC 376,399 $184.44K 20.95% 3.57% 2026-06-30
2 Geode Capital Management, LLC Custodian 266,788 $130.65K 14.84% 2.53% 2026-06-30
3 Vanguard Fiduciary Trust Co 225,938 $110.71K 12.58% 2.14% 2026-06-30
4 HRT FINANCIAL LP 107,140 $52.00K 5.91% 1.02% 2026-06-30
5 Arax Advisory Partners Custodian 93,627 $45.85K 5.21% 0.89% 2026-06-30
6 Northern Trust Corp Custodian 75,461 $36.95K 4.20% 0.72% 2026-06-30
7 ALONGSIDE, LLC 64,000 $31.34K 3.56% 0.61% 2026-06-30
8 49 WEALTH MANAGEMENT, LLC 64,000 $31.34K 3.56% 0.61% 2026-06-30
9 Cetera Investment Advisers Custodian 55,936 $27.39K 3.11% 0.53% 2026-06-30
10 KITCHING PARTNERS, LLC 50,000 $24.48K 2.78% 0.47% 2026-06-30
11 PNC Financial Services Group, Inc. Custodian 40,000 $19.60K 2.23% 0.38% 2026-06-30
12 OSAIC HOLDINGS, INC. Custodian 38,500 $18.86K 2.14% 0.37% 2026-06-30
13 LPL Financial LLC Custodian 36,379 $17.82K 2.02% 0.35% 2026-06-30
14 Morgan Stanley Custodian 22,573 $11.05K 1.26% 0.21% 2026-06-30
15 Keel Point, LLC 20,768 $10.17K 1.16% 0.20% 2026-06-30
16 Integrated Wealth Concepts LLC 20,006 $9.80K 1.11% 0.19% 2026-06-30
17 Corient Private Wealth LP 20,000 $9.79K 1.11% 0.19% 2026-06-30
18 StoneX Group Inc. 23,258 $8.67K 0.98% 0.22% 2026-06-30
19 Caitlin John, LLC 16,500 $8.08K 0.92% 0.16% 2026-06-30
20 Coston, McIsaac & Partners 17,092 $8.00K 0.91% 0.16% 2026-06-30
21 Wells Fargo & Company Custodian 15,986 $7.83K 0.89% 0.15% 2026-06-30
22 AM INVESTMENT STRATEGIES LLC 15,000 $7.00K 0.80% 0.14% 2026-06-30
23 TWO SIGMA SECURITIES, LLC 13,386 $6.55K 0.74% 0.13% 2026-06-30
24 Prospera Financial Services Inc 12,500 $6.12K 0.70% 0.12% 2026-06-30
25 Verdence Capital Advisors LLC 12,000 $5.88K 0.67% 0.11% 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

GTBP Insider Trading (Form 4)

Latest: 2025-09-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2025-09-08 Charles J Casamento Director Grant (A) +62,500 opt — EDGAR
2025-09-08 David C. Mun-Gavin Director Grant (A) +31,250 opt — EDGAR
2025-09-08 Hilary Kramer Director Grant (A) +31,250 opt — EDGAR
2025-09-08 Michael Martin Breen CEO and Director Grant (A) +300,000 opt — EDGAR
2025-09-08 Alan Louis Urban Chief Financial Officer Grant (A) +100,000 opt — EDGAR
2024-10-21 Alan Louis Urban Chief Financial Officer Grant (A) +23,335 opt — EDGAR
2023-08-15 Michael Martin Breen Executive Chairman/Interim CEO Award (A) +200,000 $0.29 $57.4K EDGAR
2023-08-15 Manu Ohri CFO & Secretary Mixed +200,000 $0.29 $57.4K EDGAR
2023-06-21 Charles J Casamento Director Grant (A) +500,000 opt — EDGAR
2023-04-11 Michael Martin Breen Executive Chairman/Interim CEO Buy (P) +50,000 $0.50 $25.0K EDGAR
2023-04-10 Manu Ohri CFO & Secretary Buy (P) +50,000 $0.50 $25.0K EDGAR
2023-02-01 Manu Ohri Chief Financial Officer Grant (A) +500,000 opt — EDGAR
2023-02-01 Michael Martin Breen Exec Chairman and Interim CEO Grant (A) +500,000 opt — EDGAR
2023-02-01 Rajesh C Md Shrotriya Director Grant (A) +500,000 opt — EDGAR
2023-02-01 Bruce Wendel Director Grant (A) +500,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

GTBP Insider Holdings

1 insider · @ $5.07
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Michael Martin Breen CEO and Director 1,142 $5.8K $25.0K 6 2025-09-08
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

GTBP Board & Officers

As of SEC filings through Sep 8, 2025
The company's insiders have not filed since Sep 8, 2025; this reflects that date.

Directors 19

Officers 13

10% owners 6

Changes in the last 10 years (32)
Jun 10, 2025David C. Mun-Gavin became a director
Jun 9, 2025The company announced the departure of Andrew J Ritter from the board in an SEC filing
May 8, 2025Andrew J Ritter became a director
May 7, 2025Hilary Kramer became a director
Jun 13, 2024Alan Louis Urban first listed as Chief Financial Officer in an SEC filing
Jun 3, 2024The company announced the departure of Manu Ohri as CFO & Secretary in an SEC filing
May 1, 2023The company announced the departure of Alan Louis Urban from the board in an SEC filing
May 1, 2023Charles J Casamento became a director
Apr 10, 2023Manu Ohri listed as CFO & Secretary (previously Chief Financial Officer) in SEC filings
Jul 19, 2022Michael Martin Breen first listed as Executive Chairman/Interim CEO in an SEC filing
Jul 19, 2022Gregory Berk first listed as Pres. of R&D, CMO in an SEC filing
Jun 9, 2022Alan Louis Urban became a director
Feb 14, 2022The company announced the departure of Gavin Choy as Acting Chief Financial Officer in an SEC filing
Feb 14, 2022Manu Ohri became Chief Financial Officer
Nov 28, 2021Gavin Choy became Acting Chief Financial Officer
Jan 13, 2021Rajesh C Md Shrotriya became a director
Jan 13, 2021Michael Martin Breen became a director
Dec 15, 2020Steven W Weldon no longer listed as a director in SEC filings
Dec 15, 2020Steven W Weldon no longer listed as CFO in SEC filings
Nov 11, 2020Gregory Berk became a director
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold GTBP
1 shown · $97.41K total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VXF Vanguard Extended Market ETF Vanguard 0.00% $97,406 — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-14.83
TTM Revenue
—
TTM Net Income
$-58.42M
TTM Op. Cash Flow
$-13.18M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31—$-3.37M$-0.11$-2.47M
Q4 '252025-12-31—$-28.90M$-4.84$-4.02M
Q3 '252025-09-30—$4.10M$1.04$-3.68M
Q2 '252025-06-30—$-30.25M$-10.92$-3.01M
Q1 '252025-03-31—$-776.00K$-0.33$-2.20M
Q4 '242024-12-31—$-3.77M$-1.66$-2.47M
Q3 '242024-09-30—$-3.41M$-1.53$-2.74M
Q2 '242024-06-30—$-3.71M$-2.17$-3.54M
Q1 '242024-03-31—$-2.27M$-1.64$-4.16M
Q4 '232023-12-31—$-2.96M$-2.17$-2.05M
Q3 '232023-09-30—$-2.42M$-1.77$-1.96M
Q2 '232023-06-30—$-1.99M$-1.49$-1.94M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-15
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
7.05
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-770.8%
ROA
-584.5%
Div Yield
2.32%
FCF Yield
-24.67%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$53.43M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
259.43K
SI % of Float
22.41%
Days to Cover
4.41
Short Vol Ratio
45.1%
Free Float
1.16M
Float %
64.2%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-15